Travere Therapeutics

The company’s chief medical officer, Jula Inrig, M.D., was named to the PharmaVoice 100 Top Industry Leaders List for 2022. The awards recognize life sciences leaders selected by PharmaVoice readers.

SAN DIEGO , May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental

The company was named a finalist for the 2022 PM30 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year award. Finalists are selected by industry experts based on innovation, talent development, and social responsibility.

The page lists job openings and information about benefits, culture, and the company’s commitment to DE&I.

Contact Travere Therapeutics for support, information or business development inquiries via phone, email or by submitting this form.

Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease.

Travere Therapeutics’ California Privacy Policy (“Policy”) applies to “Consumers” as defined by the California Consumer Privacy Act (“CCPA”) and is a supplement to Travere‘s other privacy policies or notices.

This policy addresses how Travere Therapeutics ensures individuals’ privacy when conducting clinical trials.

Travere Therapeutics' Privacy Policy describes its practices for collecting, using, and disclosing personal data and information provided to Travere.

The travere.com website is provided by Travere Therapeutics, Inc. and is subject to its Terms of Use. Visitors who use the site agree to those terms.